NCT02005900View on ClinicalTrials.gov

Effect of DHA on Lipid and Carbohydrate Metabolism Alterations and Body Fat Distribution in HIV Patients Under HAART.

PHASE3CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

June 30, 2013

Study Completion Date

October 31, 2013

Conditions
HIV-associated HypertriglyceridemiaHIV-associated HypercholesterolemiaHIV-associated Inflammatory State
Interventions
DRUG

Docosahexaenoic acid (DHA) administration to modulate Triglycerides in HIV patients under HAART

Multicenter, prospective, double-blind, randomized study of 48 weeks duration, in which the effect of 4 g daily of DHA vs 4 g daily of placebo (oleic acid) are studied on modulation of the Triglycerides and other lipids in patients with HIV infection under HAART treatment.

Trial Locations (1)

08025

Hospital de la Santa Creu i Sant Pau, Barcelona

All Listed Sponsors
collaborator

Hospital Clinic of Barcelona

OTHER

collaborator

University of Barcelona

OTHER

lead

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

OTHER

NCT02005900 - Effect of DHA on Lipid and Carbohydrate Metabolism Alterations and Body Fat Distribution in HIV Patients Under HAART. | Biotech Hunter | Biotech Hunter